Podcasts about jointly

Thursday marked the opening of an institution of learning that aims to upskill over 100,000 delivery workers. China's first "rider academy" was launched in Guangdong province, in a move that reflects the authorities' push to support the expanding courier workforce.周四，一个旨在提升10万余名配送员技能的教育机构正式揭牌。中国首家“骑手学院”在广东成立，体现出政府对不断壮大的快递与配送群体的支持力度。Jointly established by the Guangdong provincial education authority and e-commerce giant JD, the Modern Grassroots Workers Academy, widely referred to as the "rider academy", was inaugurated at Guangzhou Polytechnic University, marking China's first dedicated vocational education platform for full-time delivery personnel.由广东省教育部门与电商巨头京东联合共建的“现代基层劳动者学院”（广称为“骑手学院”）在广州科技职业技术大学揭牌，成为国内首个面向专职配送人员的职业教育平台。Lin Rupeng, director of the Guangdong Department of Education, said the academy reflects Guangdong's push to link education and talent chains more closely with the province's industrial and innovation needs, while building stronger safeguards for workers in emerging forms of employment and empowering them for future changes in the job market.广东省教育厅厅长林如鹏表示，学院体现了广东将教育链、人才链与产业链、创新链深度融合的努力，同时为新就业形态劳动者提供更完善保障，帮助其适应未来就业市场变化。"Through the enabling power of education, we are opening a new pathway for the career development of delivery riders, and by bringing universities and enterprises together, we are creating a more dynamic model of industry-education integration," he said.他说：“通过教育赋能，我们为外卖骑手开辟职业发展新通道；通过高校与企业协同，我们正在打造更加活跃的产教融合模式。”According to Feng Lei, a senior executive with JD, the academy will rely on university facilities, training centers and teaching staff across Guangdong, with Guangzhou Polytechnic University serving as the core base and several other colleges running satellite training points. Over the next three years, it will train more than 100,000 full-time riders and frontline couriers whom JD employs in the province.京东高管冯蕾介绍称，学院将依托广东多所高校的设施、培训中心和师资力量，以广州科技职业技术大学为核心基地，并在多所院校设置培训点。未来三年，学院将在广东培训超过10万名京东全职骑手与一线配送员工。The curriculum is designed to be practical and closely aligned with industry needs and development. Riders will access courses including food safety, mental well-being and English. To prepare for emerging delivery technologies, a training base for drone operators and related high-tech roles will be established, and qualified riders could be channeled into positions such as warehouse supervisors or drone pilots.课程设计强调实用性，与行业需求高度契合。骑手将学习食品安全、心理健康、英语等课程。为应对配送科技发展，学院还将建设无人机操作等高技术岗位的培训基地，合格学员将有机会转岗为仓储主管或无人机驾驶员。Guo Shuzhao, a JD rider, said the courses are closely aligned with their day-to-day work, covering not only operational skills but also safety regulations and service standards.京东骑手郭树钊表示，课程内容与日常工作高度相关，不仅涵盖操作技能，还包括安全规范和服务标准。"By completing the training to get certificates, our opportunities for career advancement will increase significantly," he said.他说：“完成培训并取得证书后，我们的晋升机会会明显增加。”The initiative comes as delivery riders, couriers, online shop owners, livestream sellers and ride-hailing drivers, classified in China as new forms of employment, become increasingly central to urban life. There are already 84 million workers nationwide engaged in such employment, data from the All-China Federation of Trade Unions showed.该举措出台之际，随着外卖骑手、快递员、网店经营者、直播带货者、网约车司机等新就业形态劳动者在城市生活中日益重要，全国已有8400万劳动者从事相关工作（全国总工会数据）。The size of this workforce and the volatility it faces have prompted several provinces to introduce structured training programs. Jiangsu launched a three-year action plan in October to expand skills training for people in these new forms of employment, covering smart-device use, labor rights and e-commerce entrepreneurship.由于这一庞大群体面临就业波动，多地已出台系统培训计划。例如江苏省今年10月启动三年行动方案，涵盖智能设备使用、劳动权益、电子商务创业等内容。The launch of the rider academy also comes amid rapid advances in automated delivery. Companies such as Meituan have expanded drone routes in major cities like Shenzhen in Guangdong, while completing more than 520,000 orders nationwide by early 2025, data from Meituan showed.骑手学院的成立，也正值自动化配送迅速发展之际。美团等企业已在深圳等城市扩大无人机配送航线，截至2025年初已完成52万余单（美团数据）。While drones and robots may reduce labor costs, Feng Lei from JD said that drones and related delivery equipment and technologies will not completely substitute for delivery personnel.尽管无人机和机器人有助于降低成本，但冯蕾表示，它们不会完全取代配送人员。She said emerging technologies "raise the skill requirements rather than eliminate the need for riders". Delivery personnel increasingly need to operate intelligent order systems and collaborate with drones and robots to complete deliveries, she said.她指出，新技术“提升了岗位技能要求，而非消灭岗位本身”。骑手未来需要操作智能派单系统，并与无人机、机器人协同完成配送。Feng Lipan, an e-commerce associate professor at South China University of Technology in Guangzhou, said the new academy is precisely intended to prepare riders for that transition.华南理工大学电子商务系副教授冯立攀表示，新学院正是为骑手应对这一转型而设。"It will reshape the public's stereotypical perception of the delivery rider profession, transforming it into a skilled occupation recognized for both mental agility and technical expertise," he said.他说：“这将重塑公众对配送职业的刻板印象，使其成为兼具思维敏捷与技术能力的技能型岗位。”industry-education integration产教融合emerging forms of employment新就业形态automated delivery自动化配送workforce volatility就业波动

Tehillah Niselow speaks to Energy Analyst, Chris Yelland See omnystudio.com/listener for privacy information.

Chinese President Xi Jinping holds an informal meeting with his French counterpart in southwest China, saying the two countries should jointly contribute to global peace and stability through dialogue and cooperation (01:13). Japanese protesters are again urging the prime minister to retract her remarks on China's Taiwan region and resign (15:18). Russian President Vladimir Putin is on his first state visit to India in four years (25:40).

Once again, Bad Bunny is dominating music headlines and social media as his brand-new “Debí Tirar Más Fotos World Tour” launched with a pair of sold-out shows at Estadio Olímpico Félix Sánchez in Santo Domingo on November 21 and 22. According to a vivid recap from DropVibe, the kickoff event was electric, cementing Bad Bunny's reputation for turning concerts into full-blown cinematic experiences. The final act erupted with fireworks and confetti, fans singing along to every word, capturing the fusion of spectacle, community, and personal connection that defines his current era.Americanonewspaper.com reports that fans lined up hours before the gates opened and remained outside well into the concert amid access snafus—underscoring the feverish demand for tickets on this tour. Bad Bunny performed fan favorites like “Callaita,” “Baile Inolvidable,” “Tití Me Preguntó,” and “Yo Perreo Sola,” but also treated Dominican Republic listeners to exclusives including “25/8” and a collaborative performance with local dembow legend El Alfa. His setlist wove together tributes to Puerto Rico, emotional storytelling, and commentary on Caribbean life, reflecting the deeper, nostalgic tone of his upcoming album, also titled Debí Tirar Más Fotos.According to TheLagosReview and NME, that sixth studio album is officially set for release on January 5, 2026. Bad Bunny previewed the album's reflective spirit—centered on the importance of memory, photographs, and living in the present—in a video teaser featuring Puerto Rican filmmaker Jacobo Morales. Fans are also already spinning his new holiday single “Pitorro de Coco,” which infuses heartbreak into festive season traditions and showcases his range as both a vocalist and storyteller.LaMezcla.com confirms the world tour is set to take him across Latin America, Australia, and Europe well into next summer, with a historic nine-show run slated in Mexico City and performances in major cities from Sydney to Buenos Aires. Jointly, the tour marks yet another high in Bad Bunny's trajectory, building on streaming records and sold-out arenas: Billboard recently hailed him as the top Latin artist of the 21st century and Spotify's most-streamed Latin artist in 2024.Adding to the current media frenzy, The Guilfordian and StingerEHS report that Bad Bunny's cultural reach is about to take center stage in the U.S. as he has been tapped to perform at Super Bowl LX, sending waves across social media as fans react to the news and speculate about potential surprise guests or genre fusions.His popularity is so influential that Yale University is keeping its course dedicated to his music and impact, with CT Public noting that his ascent—from streaming icon to halftime headliner—continues to shape cultural conversations on and off campus.On Instagram and TikTok, excerpts from the Santo Domingo concerts, behind-the-scenes moments, and snippets of his newest tracks have racked up millions of views. Fans are dissecting the album teaser's themes and his interactions with Dominican fans, where he expressed heartfelt gratitude and called the Dominican Republic his second home. As tour dates continue to sell out and excitement for the album peaks, it's clear Bad Bunny remains not just a songwriter and performer, but a global cultural phenomenon whose every move sets trends and sparks conversation.Thanks for tuning in—be sure to come back next week for more updates on Bad Bunny and all things music, culture, and entertainment. This has been a Quiet Please production; for more, check out QuietPlease.ai.Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

This accredited continuing education program is supported by an educational grant from Sanofi. Credit for the program can be obtained by visiting https://checkrare.com/learning/p-consider-rare-suspecting-and-diagnosing-cidp/ . This program, led by Jeffrey Allen, MD, Professor of Neurology at the University of Minnesota provides an overview on the diagnostic delays that often occur in patients with CIDP as well as best practices to suspect and diagnose this rare condition more efficiently. This activity has been designed to meet the educational needs of physicians specializing in family medicine, pediatrics, and neurology. Other members of the care team may also participate.Learning ObjectivesAfter participating in the activity, learners should be better able to:Describe the early symptoms of CIDP.List best practices which can be used to diagnose CIDP more efficiently.Faculty Jeffrey Allen, MDProfessor of NeurologyDepartment of NeurologyDivision of Neuromuscular MedicineUniversity of MinnesotaMinneapolis, MNDisclosure StatementAccording to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.Disclosure of relevant financial relationships are as follows:Faculty Educator/PlannerDr. Scott discloses Consultant/Educational talks: Annexon, Alexion, Amgen, CSL Behring, Takeda,BioCryst, Grifols, Argenx, Sanofi, Immunovant, ImmunoAbs, Octapharma, Alnylam, AstraZeneca, Dianthus, Johnson & Johnson, Laboratoire Français du Fractionnement et des Biotechnologies, Nuvig, Akcea Therapeutics, ImmunoPharma,Pfizer.Community Faculty/Patient (Christine Eleeson): No relevant financial relationships with any ineligible companies.Other Planners for this activity have no relevant financial relationships with any ineligible companies.This activity will review off-label or investigational information.The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.Accreditation and Credit DesignationIn support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.PhysiciansAmerican Academy of CME, Inc., designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other HCPsOther members of the care team will receive a certificate of participation.There are no fees to participate in the activity.  Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the pre-and post-program assessments. Your certificate will be emailed to you within 30 days.PrivacyFor more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm  For more information about CheckRare's privacy policy, please access https://checkrare.com/privacy/ContactFor any questions, please contact: CEServices@academycme.orgCopyright© 2025. This CME-certified activity is held as copyrighted © by American Academy of CME and CheckRare CE. Through this notice, the Academy and CheckRare CE grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).

Welcome to Calvary Lutheran Church 619 3RD AVE SW, PERHAM, MN 56573 Thank God. Share Jesus. Help Others Prayer of the Day Almighty God, you have knit your people together in one communion in the mystical body of your Son, Jesus Christ our Lord. Grant us grace to follow your blessed saints in lives of faith and commitment, and to know the inexpressible joys you have prepared for those who love you, through Jesus Christ, our Savior and Lord, who lives and reigns with you and the Holy Spirit, one God, now and forever. Amen.   Support Our Livestream Ministry—and Empower Our Youth! Each week, our YouTube, Facebook Live and our podcast services are made possible by our amazing youth media team. That's right—they run the cameras, audio, and streaming software—and we're proud to pay them for their work, helping them build life skills while serving the church. Your donation supports: Livestream costs (equipment, internet, tools) Paid media roles for our youth Continued outreach through digital ministry If you've been blessed by our services, consider giving here: https://www.calvaryperham.com/gifts Thank you for helping us serve our community—and raise up the next generation! Facebook: / calvaryperham YouTube: / @calvaryperham Podcast on Spotify https://open.spotify.com/show/7hbXujm... Podcast public site https://rss.com/podcasts/april16th2023/ Lakes 99.5 Radio Sundays at Ten Thirty AM https://player.listenlive.co/64121 TUESDAY WORSHIP 9 AM Arvig TV Channel 14 Egiving https://secure.myvanco.com/YMVS/home Website: https://calvaryperham.com/ Vanco Mobile App on Phone/Tablet: Vanco Mobile Faith Engagement has replaced the Give+ App. Search “vanco mobile faith engagement” in the app store to download on your phone or tablet, Calvary is “Calvary Lutheran Church ELCA.” Website: Click the orange E-Giving button at https://calvaryperham.com/

In his speech at the second session of the 32nd APEC Economic Leaders' Meeting, Chinese President Xi Jinping has called on Asia-Pacific economies to strengthen cooperation and create a sustainable and prosperous future.

In a landmark moment for education and cross-border cooperation, the first-ever all-island apprenticeship programme has been launched, marking a new chapter in how Ireland and Northern Ireland develop talent for the future. The Accounting Technologist Apprenticeship, developed by ATI and delivered jointly by Technological University of the Shannon and The Open University in Northern Ireland, will equip learners with cutting-edge skills in digital finance and sustainability, responding to the evolving demands of the sector. Taoiseach Micheál Martin, Tánaiste Simon Harris, Minister for Further and Higher Education, Research, Innovation and Science James Lawless TD, Minister for the Economy in Northern Ireland Dr Caoimhe Archibald, Minister of State Marian Harkin, and Gillian Doherty, COO of ATI, today officially launched the programme. Developed by ATI, the Certified Accounting Technologist's new role bridges the gap between the traditional Accounting Technician and a fully qualified accountant. The apprenticeship was created in response to the disruptive impact of AI and emerging sustainability reporting requirements. Learners will gain the skills needed to support finance teams in transitioning to digital and sustainable economic models, positioning them to add strategic value in a rapidly evolving sector. Taoiseach Micheál Martin said, "The launch of the new all-island Accounting Technologist Apprenticeship is a landmark in our shared approach to skills, opportunity and economic development. It reflects our commitment to working together across this island to prepare people for the future economy and to ensure that talent and innovation can thrive in every community. This apprenticeship is a strong example of what we can achieve through practical cooperation and shared ambition." Tánaiste Simon Harris added, "By investing in apprenticeships like this, we are showing that opportunity should know no borders and that talent can be nurtured through many different pathways. This all-island programme is a powerful example of what we can achieve through partnership, innovation and a shared commitment to preparing people for the future world of work. The Certified Accounting Technologist is an entirely new occupation, and Ireland is excited for the opportunities that it will create." Minister Lawless said: "The launch of the first apprenticeship delivered in both Ireland and Northern Ireland is a landmark achievement in our shared ambition to build a future-ready workforce across the island. It strengthens economic cooperation and competitiveness on a North-South basis and reflects the kind of practical collaboration that drives long-term prosperity. "In today's global knowledge economy, talent and ideas are our most valuable resources, and our people are our greatest natural asset. The Certified Accounting Technologist will play a vital role in linking traditional accounting and corporate reporting with cutting-edge areas such as sustainability, AI and analytics, equipping learners with the skills to lead in a rapidly evolving sector. "This is more than an apprenticeship. It is a blueprint for how we grow talent, foster innovation, and shape the future of work on an all-island basis. "I commend all partners for their vision and collaboration in delivering an apprenticeship that embodies innovation, inclusion and strategic foresight. I look forward to seeing this programme as a foundation for deeper cooperation on skills and talent development across our island." Minister Archibald said: "I am committed to expanding apprenticeship opportunities across the island, fostering cross-border collaboration and shared growth. "The new All-Island Accounting Technologist Apprenticeship is a major step forward. It enhances our curriculum and prepares learners for the evolving demands of the accounting profession. "This programme directly addresses the rise of artificial intelligence and the growing need for sustainability reporting - skills ...

US, Mexico, Costa Rica, Jamaica Jointly Bid to Host 2031 FIFA Women's World Cup

This program, led by Christiaan Scott, MD, Professor of Pediatric Rheumatology at the University of Ottawa and Raphaella Stander, MBCHB, Pediatrician at Atlantic Children's Practice, focused  on three case studies to provide physicians with education on best practices to: 1) suspect and diagnose FOP, 2) monitor and manage younger children with FOP, and 3) monitor and manage older children and adults with FOP. This accredited CME program provides healthcare professional with timely and practical education on fibrodysplasia ossificans progressiva (FOP). It is supported by an educational grant from Ipsen Biopharmaceuticals.To obtain CME credit, visit https://checkrare.com/learning/p-case-studies-in-diagnosing-and-managing-fop/ Target AudienceThis activity has been designed to meet the educational needs of physicians specializing in pediatrics, rheumatology, genetics, family medicine, and orthopedics. Other members of the care team may also participate.Learning ObjectivesAfter participating in the activity, learners should be better able to:Apply best practices for suspecting and diagnosing FOP.List best practices for managing young children with FOP.Identify best practices to manage older children and adults with FOP.Christiaan Scott, Professor of Medicine, University of OttawaRaphaella Stander, MBCHB, Pediatrician, Atlantic Children's PracticeDisclosure StatementAccording to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.Disclosure of relevant financial relationships are as follows:Faculty Educator/PlannerDr. Scott discloses the following relevant financial relationships with ineligible companies:Grant/Research Support: Regeneron*, Incyte*, Janssen*, Roche*; Speaker's Bureau:  Ipsen*, Regeneron*, Springer*, Jannsen**Relationships have endedDr. Stander has no relevant financial relationships with ineligible companies.Other Planners for this activity have no relevant financial relationships with any ineligible companies.This activity will review off-label or investigational information.The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.Accreditation and Credit DesignationIn support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.PhysiciansAmerican Academy of CME, Inc., designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other HCPsOther members of the care team will receive a certificate of participation.There are no fees to participate in the activity.  Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the pre and post-program assessments. Your certificate will be emailed to you within 30 days.PrivacyFor more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm  For more information about CheckRare's privacy policy, please access https://checkrare.com/privacy/ContactFor any questions, please contact: CEServices@academycme.orgCopyright© 2025. This CME-certified activity is held as copyrighted © by American Academy of CME and CheckRare CE. Through this notice, the Academy and CheckRare CE grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).

With book bans in public schools rising to levels unseen since the McCarthy era Red Scare of the 1950s, the Eleanor Roosevelt Banned Book Awards ceremony at the Bardavon in Poughkeepsie, N.Y. will be presented jointly with PEN America on Saturday, October 11th. Author Jennifer Finney Boylan, PEN America's president, will be the keynote speaker.Ten honorees include best-selling author Margaret Atwood (The Handmaid's Tale), who will receive the Eleanor Roosevelt Lifetime Achievement Award at the Bardavon in Poughkeepsie on October 11th.

The Midwest Regional Broadcasters Clinic is where broadcast engineers and technologists gather each year to learn, share, and connect. Hosted in Wisconsin, this premier event features deep-dive sessions on both cutting-edge and legacy technologies, a vibrant trade show floor, and plenty of opportunities to network with peers from across the Midwest and beyond. Jointly organized by the Wisconsin and Minnesota Broadcasters Associations along with SBE chapters from both states, it’s a true collaboration for the industry. This year, TWiRT is once again going live from the trade show floor—right in the middle of the action—bringing you the latest insights, innovations, and conversations from one of the broadcast community’s most valuable gatherings. Guests:Jim Armstrong - Senior Director of Sales US/Canada at Telos AllianceWilliam Kerkhof - Director of Engineering RTVF at University of Wisconsin Oshkosh Paul Kriegler - US Manager Omnia Sales at Telos AlliancePaul Stewart - President at Summit Technology GroupBrad Young - Sales Manager at WideOrbit Keith Paglia - Sales and Marketing at Sprite Media, Inc.Seth Stevenson - Broadcast Engineer Intern at Northwestern MediaEarl Sondreal - Director of Sales & Marketing, Americas at InovonicsBob Goff - General Manager at Heart of Wisconsin Media LLC Host:Kirk Harnack, The Telos Alliance, Delta Radio, Star94.3, South Seas, & Akamai BroadcastingFollow TWiRT on Twitter and on Facebook - and see all the videos on YouTube.TWiRT is brought to you by:Broadcasters General Store, with outstanding service, saving, and support. Online at BGS.cc. Broadcast Bionics - making radio smarter with Bionic Studio, visual radio, and social media tools at Bionic.radio.Aiir, providing PlayoutONE radio automation, and other advanced solutions for audience engagement.Angry Audio and the new Rave analog audio mixing console. The new MaxxKonnect Broadcast U.192 MPX USB Soundcard - The first purpose-built broadcast-quality USB sound card with native MPX output. Subscribe to Audio:iTunesRSSStitcherTuneInSubscribe to Video:iTunesRSSYouTube

The Midwest Regional Broadcasters Clinic is where broadcast engineers and technologists gather each year to learn, share, and connect. Hosted in Wisconsin, this premier event features deep-dive sessions on both cutting-edge and legacy technologies, a vibrant trade show floor, and plenty of opportunities to network with peers from across the Midwest and beyond. Jointly organized by the Wisconsin and Minnesota Broadcasters Associations along with SBE chapters from both states, it's a true collaboration for the industry. This year, TWiRT is once again going live from the trade show floor—right in the middle of the action—bringing you the latest insights, innovations, and conversations from one of the broadcast community's most valuable gatherings.

The accredited CME program highlights the latest clinical research about hemophilia, a rare, genetic bleeding disorder. Led by Dr. Steven Pipe, MD, this activity provides a summary of clinically relevant data presented at the International Society of Thrombosis and Haemostatis Congress (ISTH 2025) that can enhance the care of patients with hemophilia. This program is supported by an educational grant from Sanofi.To receive CME credit, visit https://checkrare.com/learning/p-isth2025-module1-hemophilia-clinical-research-highlights/Target AudienceThis activity has been designed to meet the educational needs of physicians specializing in hemophilia. Other members of the care team may also participate.Learning ObjectivesAfter participating in the activity, learners should be better able to:Describe the latest research being presented to better manage individuals with hemophilia and its clinical relevance.Steven Pipe, MDProfessor of Medicine,University of Michigan Disclosure StatementAccording to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated. Disclosure of relevant financial relationships are as follows:Faculty Educator/PlannerDr. Pipe discloses the following relevant financial relationships with ineligible companies:Consultant: Bayer, BioMarin, CSL Behring, Hema Biologics, Inovio, LFB, Metagenomi, Novo Nordisk, Pfizer, Poseida Therapeutics, Roche/Genentech, Sanofi, Takeda, Spark TherapeuticsScientific Advisory Committee: GeneVentiv, Equilibra BioscienceGrant/Research Support: Siemens, YewSaving Other Planners for this activity have no relevant financial relationships with any ineligible companies. This activity will review off-label or investigational information. The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information. Accreditation and Credit DesignationIn support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.PhysiciansAmerican Academy of CME, Inc., designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other HCPsOther members of the care team will receive a certificate of participation. ContactFor any questions, please contact: CEServices@academycme.orgCopyright© 2025. This CME-certified activity is held as copyrighted © by American Academy of CME and CheckRare CE. Through this notice, the Academy and CheckRare CE grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).

The accredited CME program highlights the latest clinical research about iTTP, a rare thrombotic disorder. Led by Shruti Chaturvedi, MD, this activity provides a summary of clinically relevant data presented at the International Society of Thrombosis and Haemostatis Congress (ISTH 2025) that can enhance the care of patients with iTTP. This program is supported by an educational grant from Sanofi.To receive CME credit, go to https://checkrare.com/learning/p-isth2025-module3-immune-thrombotic-thrombocytopenic-purpura-ittp-clinical-research-highlights/Target AudienceThis activity has been designed to meet the educational needs of physicians specializing in iTTP. Other members of the care team may also participate.Learning ObjectivesAfter participating in the activity, learners should be better able to:Describe the latest research being presented to better manage individuals with iTTP and its clinical relevance. Shruti Chaturvedi, MDAssistant Professor of MedicineJohns Hopkins Disclosure StatementAccording to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated. Disclosure of relevant financial relationships are as follows:Faculty Educator/PlannerDr. Chaturvedi discloses the following relevant financial relationships with ineligible companies:Scientific Advisory Board/Consultant: Sanofi, Takeda, Sobi, argenx, Star Pharma, RallyBio, Novartis, AlexionGrant/Research Support: Sanofi, Sobi, argenx Other Planners for this activity have no relevant financial relationships with any ineligible companies. This activity will review off-label or investigational information. The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information. Accreditation and Credit DesignationIn support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.PhysiciansAmerican Academy of CME, Inc., designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other HCPsOther members of the care team will receive a certificate of participation. There are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the pre and post-program assessments. Your certificate will be emailed to you within 30 days. PrivacyFor more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm  For more information about CheckRare's privacy policy, please access https://checkrare.com/privacy/ContactFor any questions, please contact: CEServices@academycme.orgCopyright© 2025. This CME-certified activity is held as copyrighted © by American Academy of CME and CheckRare CE. Through this notice, the Academy and CheckRare CE grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).

This accredited CME program highlights the latest clinical research about immune thrombocytopenia (ITP), a rare thrombotic disorder. Led by Shruti Chaturvedi, MD, this program provides a summary of clinically relevant data presented at the International Society of Thrombosis and Haemostatis Congress (ISTH 2025) that can enhance the care of patients with ITP. This program is supported by an educational grant from Sanofi.To receive CME credit, go to https://checkrare.com/learning/p-isth2025-module2-immune-thrombocytopenia-clinical-research-highlights/Target AudienceThis activity has been designed to meet the educational needs of physicians specializing in ITP. Other members of the care team may also participate.Learning ObjectivesAfter participating in the activity, learners should be better able to:Describe the latest research being presented to better manage individuals with ITP and its clinical relevance.FacultyShruti Chaturvedi, MDAssistant Professor of Medicine,Johns Hopkins Disclosure StatementAccording to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated. Disclosure of relevant financial relationships are as follows:Faculty Educator/PlannerDr. Chaturvedi discloses the following relevant financial relationships with ineligible companies:Scientific Advisory Board/Consultant: Sanofi, Takeda, Sobi, argenx, Star Pharma, RallyBio, Novartis, AlexionGrant/Research Support: Sanofi, Sobi, argenx Other Planners for this activity have no relevant financial relationships with any ineligible companies. This activity will review off-label or investigational information. The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.Accreditation and Credit DesignationIn support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.PhysiciansAmerican Academy of CME, Inc., designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other HCPsOther members of the care team will receive a certificate of participation. There are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the pre and post-program assessments. Your certificate will be emailed to you within 30 days. PrivacyFor more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm  For more information about CheckRare's privacy policy, please access https://checkrare.com/privacy/ContactFor any questions, please contact: CEServices@academycme.orgCopyright© 2025. This CME-certified activity is held as copyrighted © by American Academy of CME and CheckRare CE. Through this notice, the Academy and CheckRare CE grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).

This program is supported by an educational grant from UCB, Inc. This accredited CME program highlights the latest clinical research about myasthenia gravis, a rare, autoimmune disease that targets the neuromuscular junction.  This program, led by Dr. James Howard Jr, provides a summary of clinically relevant data presented at the American Academy of Neurology Annual Meeting (AAN 2025) held in San Diego, CA that can enhance the care of patients with myasthenia gravis.  To obtain CME credit for this program, visit https://checkrare.com/learning/p-myasthenia-gravis-clinical-research-highlights-aan-2025/Target AudienceThis activity has been designed to meet the educational needs of physicians specializing in neurology, ophthalmology, rheumatology, and family practice. Other members of the care team may also participate.Learning ObjectivesAfter participating in the activity, learners should be better able to:Describe the latest research being presented to better manage individuals with myasthenia gravis and its clinical relevance.FACULTY James F. Howard Jr, MD, FAANProfessor of NeurologyUniversity of North Carolina at Chapel HillDisclosure StatementAccording to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.Disclosure of relevant financial relationships are as follows:Faculty Educator/PlannerDr. Howard discloses the following relevant financial relationships with ineligible companies:Advisory Board/Consultant: Alexion AstraZeneca Rare Disease, Amgen, argenx, Biohaven Ltd, Cartesian Therapeutics, CoreEvitas, Curie.bio, Hansa Biopharma, H. Lundbeck A/S, Merck EMD Serono, NMD Pharma, Novartis Pharma, Regeneron Pharmaceuticals, Sanofi US, Seismic Therapeutics, TG Therapeutics, Toleranzia AB, and UCB PharmaGrant/Research Support: Ad Scientiam, Alexion AstraZeneca Rare Disease, argenx, Cartesian Therapeutics, NMD Pharma, and UCB PharmaOther Relationships: non-financial support (eg travel) Alexion AstraZeneca Rare Disease, argenx, Biohaven Ltd, Cartesian Therapeutics, Toleranzia AB, and UCB Pharma.Other Planners for this activity have no relevant financial relationships with any ineligible companies.This activity will review off-label or investigational information.The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.CREDIT Accreditation and Credit DesignationIn support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.PhysiciansAmerican Academy of CME, Inc., designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other HCPsOther members of the care team will receive a certificate of participation.There are no fees to participate in the activity.  Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the pre and post-program assessments. Your certificate will be emailed to you within 30 days.PrivacyFor more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm  For more information about CheckRare's privacy policy, please access https://checkrare.com/privacy/ContactFor any questions, please contact: CEServices@academycme.orgCopyright© 2025. This CME-certified activity is held as copyrighted © by American Academy of CME and CheckRare CE. Through this notice, the Academy and CheckRare CE grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).

Learn more at TheCityLife.org

In this eye-opening episode of Don't Go Broke Trying, Reni sits down with Aimee Schalles and Amanda Baron, two practicing lawyers and co-founders of Jointly, a legal tech platform making prenups and cohabitation agreements more accessible for everyday Canadians.Together, they unpack the stigma around prenups and explain why legal agreements like prenups, postnups, and cohabitation contracts are important tools for anyone in a serious relationship, not just for celebrities and millionaires.From breaking down what these agreements really mean, to busting the myths that make people avoid them, this conversation will make you rethink what financial protection in love actually looks like.What You'll Learn in This Episode:The difference between prenups, postnups, and cohabitation agreementsWhy everyone, not just wealthy couples should consider oneHow to bring up a prenup with your partner (without killing the romance)What a prenup can and can't include (especially when it comes to kids, houses, and businesses)How to use these agreements as tools of care, not conflictThis episode will leave you with a clear understanding of what prenups are (and aren't), why they're not just for the rich and famous, and how they can actually strengthen your relationship not weaken it.Resources Mentioned: Learn more about Jointly: https://getjointly.ca/Prenup legal course by Jointly: https://getjointly.ca/learning-center/Follow Jointly: https://www.instagram.com/getjointly/Watch on Youtube: https://youtu.be/EqUhVt7hOws?si=QrW5eM6iRqF-83eQ Connect With My Guests:Aimee - https://www.linkedin.com/in/aimeeschalles/Amanda - https://www.linkedin.com/in/amandabaron/Join Don't Go Broke Collective: ⁠https://www.skool.com/dont-go-broke-collective/aboutConnect With Us!Follow the podcast on Instagram: ⁠⁠⁠https://instagram.com/dontgobroketrying Follow Reni on Instagram: ⁠⁠⁠https://www.instagram.com/xoreni Visit our website: ⁠⁠⁠⁠renitheresource.com/category/podcast⁠⁠⁠⁠Follow on Twitter: ⁠⁠⁠⁠twitter.com/dgbtpod⁠⁠⁠⁠Subscribe to Reni's YouTube: https://youtube.com/xoreniDISCLAIMER: The views and opinions shared on this channel are for informational and educational purposes only. This is NOT financial advice. Always do your own research and due diligence before investing.

AP correspondent Charles de Ledesma reports Ukraine is forging ahead with embryonic plans for joint weapons production with some of its international allies, as U.S. says it is halting some arms shipmentsfor Kyiv.

You've probably heard the saying, “A man who represents himself in court has a fool for a client.” While most of us wouldn't go to court alone, the rise of do-it-yourself legal tool kits makes it tempting to go without professional guidance when creating an estate plan. But it's important to understand that off-the-shelf home remedies can expose your assets to unnecessary risk and jeopardize your family's financial future. From emotional blind spots to technical errors, even the smartest people can make costly mistakes without proper legal help. So, before you get carried away with DIY enthusiasm, tune in to learn the hidden costs and common pitfalls of do-it-yourself legal tools.    WHAT YOU NEED TO KNOW (00:00) Episode introduction. (02:56) When non-professionals use off-the-shelf tools to create a trust, will, power of attorney (PoA), or estate plan, strategic missteps and technical mistakes often go unnoticed until it's too late. (05:18) Estate planning and elder law are highly complex even for attorneys who specialize in these areas. (07:35) Often, basic DIY legal kits don't keep pace with state-specific laws and are not able to address “what if” scenarios such as changes in marital status, unexpected death or disability, protection of government benefits, etc.   (09:21) The use of beneficiaries to avoid probate does not provide protection of assets or safeguard against mishandling of funds and property.  (11:07) Jointly owned assets can have significant tax implications. (12:33) Long-term care eligibility and asset protection are complicated and require thoughtful, expert strategies. (16:43) Powers of attorney should be very specific. Most DIY kits do not contain the appropriate language. (23:23) Can you use a DIY kit and have everything turn out well? Yes, but there are many situations that a DIY kit cannot provide for—and those are the protections that a professionally created plan can anticipate.     ABOUT BELLOMO & ASSOCIATES Jeffrey R. Bellomo, the founder of Bellomo & Associates, is a licensed and certified elder law attorney with a master's degree in taxation and a certificate in estate planning. He explains complex legal and financial topics in easy-to-understand language. Bellomo & Associates is committed to providing education so that what happened to the Bellomo family doesn't happen to your family. We conduct free workshops on estate planning, crisis planning, Medicaid planning, special needs planning, probate administration, and trust administration. Visit our website (https://bellomoassociates.com/) to learn more.   LINKS AND RESOURCES MENTIONED Bellomo & Associates workshops:https://bellomoassociates.com/workshops/ Life Care Planning The Three Secrets of Estate Planning Nuts & Bolts of Medicaid For more information, call us at (717) 845-5390. Connect with Bellomo & Associates on Social Media Tune in Saturdays at 7:30 a.m. Eastern to WSBA radio: https://www.newstalkwsba.com/ X (formerlyTwitter):https://twitter.com/bellomoassoc YouTube: https://www.youtube.com/user/BellomoAssociates Facebook:https://www.facebook.com/bellomoassociates Instagram:https://www.instagram.com/bellomoassociates/ LinkedIn:https://www.linkedin.com/in/bellomoandassociates WAYS TO WORK WITH JEFFREY BELLOMO Contact Us:https://bellomoassociates.com/contact/ Practice areas:https://bellomoassociates.com/practice-areas/      

This program is supported by educational grants from Amicus Therapeutics, Inc. and Chiesi USA Inc.Fabry disease is an inherited lysosomal storage disease caused by mutations in the GLA gene, disrupting the function of the enzyme, α-galactosidase. This results in the accumulation of globotriaosylceramide (GL-3) and its deacylated form, globotriaosylsphingosine (lyso-GL-3), leading to progressive disruption of multiple organ systems. There are currently three treatment options available for Fabry disease, including two enzyme replacement therapies, agalsidase beta and pegunigalsidase alfa, and a chaperone therapy, migalastat. There are also other treatments in development (e.g., gene therapy, other enzyme replacement therapies) and some that are available in other countries (e.g., agalsidase alfa). Due to the small patient population and variability in Fabry disease severity, it is challenging to develop properly powered, placebo-controlled clinical trials. As such, data shared at conferences like WORLDSymposium 2025 are crucial for guiding best practices in this disease area. This program, led by Dr. Eric Wallace, provides a summary of clinically relevant data presented at WORLDSymposium 2025 that can enhance the care of patients with Fabry disease.  Target AudienceThis activity has been designed to meet the educational needs of physicians specializing in neurology, nephrology, cardiology, gastroenterology, ophthalmology, and dermatology. Other members of the care team may also participate.Learning ObjectivesAfter participating in the activity, learners should be better able to: Describe the latest research being presented to better manage individuals with Fabry disease and its clinical relevance.Eric Wallace, MDProfessor of MedicineDepartment of NephrologyUniversity of Alabama Medical SchoolDisclosure StatementAccording to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.Disclosure of relevant financial relationships are as follows:Faculty Educator/PlannerDr. Wallace discloses the following relevant financial relationships with ineligible companies:Advisory Board Consultant: Sanofi-Genzyme, Chiesi, Kyowa Kirin, Sangamo, NateraGrant/Research Support: Sanofi-Genzyme, Chiesi, Uniqure, Idorsia, Amicus Other Planners for this activity have no relevant financial relationships with any ineligible companies.This activity will review off-label or investigational information.The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.Accreditation and Credit DesignationIn support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.PhysiciansAmerican Academy of CME, Inc., designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other HCPsOther members of the care team will receive a certificate of participation.There are no fees to participate in the activity.  Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the pre and post-program assessments. Your certificate will be emailed to you within 30 days.Hardware/Software RequirementsWindows Requirements: • Operating system: Windows XP Service Pack 2 or later • Browser: Internet Explorer 7 or later, Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connectionMacintosh Requirements: • Operating system: Mac OS X v10.3 or later • Browser: Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connectionPrivacyFor more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm  For more information about CheckRare's privacy policy, please access https://checkrare.com/privacy/ContactFor any questions, please contact: CEServices@academycme.orgCopyright© 2025. This CME-certified activity is held as copyrighted © by American Academy of CME and CheckRare CE. Through this notice, the Academy and CheckRare CE grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).

Un breve aggiornamento rispetto all'ultima puntata di Actually, dedicata alla pubblicità sui podcast. Nella Big Story, una conversazione tra Richi e Francesca Rizzi, CEO di Jointly, dedicata al rapporto tra la gen z e il lavoro, sulla base di una ricerca quali-quantitativa realizzata in partnership, che ha coinvolto quasi 200 giovani ragazzi e ragazze di tutta Italia. Questo podcast e gli altri nostri contenuti sono gratuiti anche grazie a chi ci sostiene con Will Makers. Sostienici e accedi a contenuti esclusivi su ⁠⁠⁠⁠⁠⁠willmedia.it/abbonati Learn more about your ad choices. Visit megaphone.fm/adchoices

Send us a textJoin us as we sit down with Enrolled Agent, and Founder of Golden Lion Tax Solutions, Morgan Q. Anderson, to discuss everything you need to know about Innocent Spouse Protection and Relief when filing jointly on an income tax return.As a leading divorce firm in Portland, our attorneys provide guidance on custody, alimony, separation, estate planning, and more. Learn what to expect in Oregon and Washington divorce cases and how we can help.If you would like to speak with one of our attorneys, please call our office at (503) 227-0200, or visit our website at https://www.pacificcascadelegal.com.To learn more about Morgan and how she can help you with your tax questions, you can visit her website at: https://www.goldenliontaxsolutions.com/Disclaimer: Nothing in this communication is intended to provide legal advice nor does it constitute a client-attorney relationship, therefore you should not interpret the contents as such.

Ogni persona che lascia il lavoro ha un costo medio per l'azienda pari a circa il 50% del suo stipendio annuo, dall'altro lato un piano incentrato sul benessere organizzativo e personale (es. asili nido, campus estivi, sportello psicologico, servizi di rilevanza sociale) supera in termini di produttività di oltre quattro volte il valore economico dell'investimento sostenuto dall'impresa. Cosa vuol dire tutto questo in termini pratici? Perché i lavoratori se ne vanno e quali politiche dovrebbero e potrebbero mettere in atto le aziende per migliorare il cosiddetto work life balance? Ne parliamo nella puntata di oggi con Francesca Rizzi, CEO e CO-Founder di Jointly. … Clicca qui per la promo primavera ... Qui il link per iscriversi al canale Whatsapp di Notizie a colazione: https://whatsapp.com/channel/0029Va7X7C4DjiOmdBGtOL3z Per iscriverti al canale Telegram: https://t.me/notizieacolazione ... Qui gli altri podcast di Class Editori: https://milanofinanza.it/podcast Musica https://www.bensound.com Learn more about your ad choices. Visit megaphone.fm/adchoices

This CME program, hosted by Jean Elwing, MD, of the University of Cincinnati College of Medicine provides an overview of the latest clinical research about PAH presented at CHEST 2024.PAH is a rare, progressive disorder characterized by high blood pressure in the pulmonary arteries. Symptoms of PAH include shortness of breath (dyspnea) especially during exercise, chest pain, and fainting episodes. The progressive nature of this disease means that an individual may experience only mild symptoms at first, but will eventually require treatment and medical care to maintain a reasonable quality of life. There are numerous treatment options and options in development for persons with PAH and it is imperative clinicians who manage these patients stay up-to-date on the latest clinical research. Target AudienceThis activity has been designed to meet the educational needs of physicians specializing in pulmonology, cardiology, rheumatology, and radiology. Other members of the care team may also participate.Learning ObjectivesDescribe the latest research being presented to better manage people with PAH and its clinical relevance.CME CreditTo obtain credit, visit https://checkrare.com/learning/p-pah-clinical-research-highlights-chest-2024/Faculty/ DisclosureAccording to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.Disclosure of relevant financial relationships are as follows:Dr. Elwing discloses the following relevant financial relationships with ineligible companies:Advisory Board Consultant: United Therapeutics, Aerovate Therapeutics, Gossamer Bio, Liquidia, Merck, Janssen/Actelion/Johnson & Johnson, Lung LLC, PulmovantGrant/Research Support: United Therapeutics, Gossamer Bio, Bayer, Acceleron/Merck, Altavant Sciences, Aerovate Therapeutics, Pharmosa Biopharm/Liquidia, Actelion/Janssen/Johnson & Johnson, Lung LLC, PulmovantSpeaking Honorarium: United TherapeuticsPlanners for this activity have no relevant financial relationships with any ineligible companies.This activity will review off-label or investigational information.The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically and draw conclusions only after careful consideration of all available scientific information.Accreditation and Credit DesignationIn support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.PhysiciansAmerican Academy of CME, Inc., designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other HCPsOther members of the care team will receive a certificate of participation.PrivacyFor more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm  For more information about CheckRare's privacy policy, please access https://checkrare.com/privacy/ContactPlease contact: CEServices@academycme.org for any comments or questions.;Copyright © 2025. This CME-certified activity is held as copyrighted © by American Academy of CME and CheckRare CE. Through this notice, the Academy and CheckRare CE grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).

Hereditary angioedema (HAE) is a rare condition often due to reduced levels C1-inhibitor, which is a protein involved in various physiological processes in plasma, most notably with the complement system. C1-inhibitor also binds and inhibits plasma kallikrein and factor XIa, thereby affecting bradykinin production. It is believed that the disruptions of these processes cause fluid to leak from the blood to connective tissue, leading to HAE attacks. Owing to its rarity, HAE is often poorly recognized, leading to misdiagnoses and significant diagnostic delays. Being aware of the early signs and symptoms of this condition can lead to faster diagnosis and the use of effective therapies.This program is supported by independent medical education grants from Takeda. To earn CME credit please visit https://checkrare.com/learning/p-consider-rare-suspecting-and-diagnosing-hereditary-angioedema/lessons/consider-rare-suspecting-and-diagnosing-hereditary-angioedema-module/  Target AudienceThis activity has been designed to meet the educational needs of physicians specializing in primary care, pediatrics, emergency care, otolaryngology, gastroenterology, and dermatology .Other members of the care team may also participate.Learning ObjectivesAfter participating in the activity, learners should be better able to:- Describe the early symptoms of HAE and its clinical relevance.- Apply best practices to diagnose HAE more efficiently to reduce diagnostic delays. Faculty Jonathan A Bernstein, MDProfessor of MedicineUniversity of Cincinnati Department of Internal MedicineDivision of Immunology, Allergy SectionPartner Advanced Allergy Services, LLCPartner Bernstein Clinical Research Center Disclosure StatementAccording to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.Disclosure of relevant financial relationships are as follows:Dr. Bernstein discloses the following relevant financial relationships with ineligible companies:Advisory Board Consultant: Takeda/Shire, CSL Behring, KalVista, Pharming, Biocryst, Ionis, Intellia, Pharvaris, Astria and BiomarinGrant/Research Support: Takeda/Shire, CSL Behring, KalVista, Pharming, Biocryst, Ionis, Intellia, Pharvaris, Astria and BiomariSpeaker's Bureau: PharmingPlanners for this activity have no relevant financial relationships with any ineligible companies.This activity will review off-label or investigational information.The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.Accreditation and Credit DesignationIn support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.PhysiciansAmerican Academy of CME, Inc., designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other HCPsOther members of the care team will receive a certificate of participation.There are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the pre and post-program assessments. Your certificate will be emailed to you within 30 days.ContactFor any questions, please contact: CEServices@academycme.orgCopyright© 2025. This CME-certified activity is held as copyrighted © by American Academy of CME and CheckRare CE. Through this notice, the Academy and CheckRare CE grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).

Questions? Thoughts? Send a Text to The Optometry Money Podcast!The student loan landscape is shifting again! In this episode, Evon breaks down the latest updates on the SAVE Plan, the recent court rulings, and what these changes mean for optometrists navigating their student loan repayment.With major legal challenges in play, borrowers on SAVE are currently in interest-free forbearance, but the future of the program remains uncertain. Evon unpacks the key takeaways from the recent 8th Circuit Court of Appeals decision, discusses potential next steps, and shares what optometrists should consider when making student loan repayment decisions.What You'll Learn:✅ Background on the SAVE Plan & Legal Challenges – Why the courts put SAVE on hold and what's next✅ What This Means for Optometrists – How the latest rulings impact those on SAVE, PAYE, and IBR plans✅ Should You Switch Plans? – Factors to consider before making a move✅ Tax Strategies for Student Loan Borrowers – Filing tips to optimize student loan repayment✅ Preparing for Uncertainty – Practical steps to protect your financial futureKey Takeaways:

DEAR PAO: Co-ownership may exist over property jointly purchased by common-law spouses while one party is still legally married to another | Mar. 6, 2025Visit our website at https://www.manilatimes.netFollow us:Facebook - https://tmt.ph/facebookInstagram - https://tmt.ph/instagramTwitter - https://tmt.ph/twitterDailyMotion - https://tmt.ph/dailymotionSubscribe to our Digital Edition - https://tmt.ph/digitalSign up to our newsletters: https://tmt.ph/newslettersCheck out our Podcasts:Spotify - https://tmt.ph/spotifyApple Podcasts - https://tmt.ph/applepodcastsAmazon Music - https://tmt.ph/amazonmusicDeezer: https://tmt.ph/deezerStitcher: https://tmt.ph/stitcherTune In: https://tmt.ph/tunein#TheManilaTimes Hosted on Acast. See acast.com/privacy for more information.

The budget and the RBI monetary policy committee need to work in tandem in the next two weeks to rescue India's flagging growth story, Economist Radhika Pandey and Deputy Editor TCA Sharad Raghavan discuss in ThePrint #MacroSutra. 

Democratic and Republican leaders of the Minnesota Senate say they have come to an agreement to jointly run the chamber while it is tied for much of this month. Meanwhile, in the Minnesota House, Democrats took their oaths of office Sunday — as part of an effort to block Republican control when the legislative session begins.And three people died in a two-vehicle, head-on crash Sunday afternoon in central Minnesota. The Minnesota State Patrol says it happened on Highway 169 near Mille Lacs Lake. This is a MPR News morning update, hosted by Phil Picardi. Music by Gary Meister.Find these headlines and more at mprnews.org.Bumpier takeoff on tap for Minnesota Legislature's session opening amid early oaths, election disputesRead the latest edition of the Minnesota Today newsletter.Subscribe on Apple Podcasts, Spotify, YouTube or RSS.

Singapore SME Choon Huat Engineering took home First Prize at the 30th Enterprise 50 (E50) Awards with Guest-of-Honour Deputy Prime Minister Heng Swee Keat. On the Saturday Mornings Show "Singapore Home Brew Segment", CEO Oh Chee Yong talks with host Glenn van Zutphen and co-host Neil Humphreys. Oh discusses how his third-generation family-run business is shattering traditional ways of thinking in the local construction industry by supplying machinery that cuts up to 80% of current noise and emission levels on building sites. Jointly organised by The Business Times (BT) and KPMG in Singapore Commemorating the 30th anniversary of the Enterprise 50 Awards celebrate champions of change and ignite the future of Singapore's private enterprise community. E50 Awards recognise the 50 most enterprising local, privately-held companies that are contributing to the economic development of Singapore, at home and abroad.See omnystudio.com/listener for privacy information.

This 30-minute CME-accredited program, hosted by John Kuruvilla, MD, discusses best practices for talking to patients with hematologic malignancies about possibly participating in clinical trials.Jointly Provided by American Academy of CME and CheckRare CE.Support for this accredited continuing education activity has been made possible through educational grant from Merck.Estimated time to complete: 0.5 hours Start date: November 30, 2024End date: November 30, 2025  Activity FacultyJohn Kuruvilla, MDHematologist / Clinical InvestigatorPrincess Margaret Cancer CentreProfessor of MedicineUniversity of Toronto Target AudienceThis activity has been designed to meet the educational needs of physicians specializing in hematology-oncology. Other healthcare providers, including NPs and PAs, may also participate. Learning ObjectivesAfter participating in the activity, learners should be better able to- Describe the importance of clinical trials in furthering the science of hematologic malignancies treatment.- Describe and utilize best practices for engaging patients in shared decision making regarding clinical trial participation. Accreditation and Credit DesignationIn support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. PhysiciansAmerican Academy of CME, Inc., designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other HCPsOther members of the care team will receive a certificate of participation. Disclosure StatementAccording to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.Disclosure of relevant financial relationships are as follows: Faculty Educator/PlannerDr. Kuruvilla discloses the following relevant financial relationships with ineligible companies:Honoraria: AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Beigene, Genmab, Gilead Sciences, GlaxoSmithKline, Incyte, Janssen, Karyopharm, Merck, Novartis, Pfizer, Roche, Seattle GeneticsConsultant: AbbVie, Bristol Myers Squibb, Gilead Sciences/Kite, Merck, Roche, Seattle GeneticsGrant/Research Support: AstraZeneca, Kite, Merck, Novartis, RocheData Safety Monitoring Board: KaryopharmPlanners for this activity have no relevant financial relationships with any ineligible companies. This activity will not review off-label or investigational information. The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information. Method of ParticipationThere are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please go to https://checkrare.com/learning/p-hematologic-malignancies-and-clinical-trial-participation-a-shared-decision-making-approach/   PrivacyFor more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm  For more information about CheckRare's privacy policy, please access https://checkrare.com/privacy/ContactFor any questions, please contact: CEServices@academycme.org               

Jointly Provided by the American Academy of CME and CheckRare CE Inc.Support for this accredited continuing education activity has been made possible through educational grant from argenx US Inc. and UCB.Estimated time to complete: 0.25 hoursStart date: November 7, 2024End date: November 6, 2025This quarter-hour CME-accredited program, hosted by Richard J. Nowak, MD, MS, discusses the safety and efficacy of neonatal fragment crystallizable receptor (FcRn)-directed therapies for patient with myasthenia gravis.To obtain CME credit, visit https://checkrare.com/learning/p-fcrn-and-myasthenia-gravis-treatment-options/ Activity FacultyRichard J. Nowak, MD, MSDirector, Program in Clinical & Translational Neuromuscular Research (CTNR) Director, Yale Myasthenia Gravis Clinic Associate Professor of Neurology Division of Neuromuscular MedicineDepartment of Neurology Yale School of Medicine New Haven, CTTarget AudienceThis activity has been designed to meet the educational needs of physicians specializing in neurology and ophthalmology who may be involved in the diagnosis and care of individuals with MG. Other healthcare providers, including neurology NPs and PAs, may also participate. Learning ObjectivesAfter participating in the activity, learners should be better able toDescribe the efficacy of the treatment options for MG that target FcRn.Compare the safety of the treatment options for MG that target FcRn.Accreditation and Credit DesignationIn support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.PhysiciansAmerican Academy of CME, Inc., designates this enduring material for a maximum of 0.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Other HCPsOther members of the care team will receive a certificate of participation.Disclosure StatementAccording to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and all of the relevant financial relationships listed for these individuals have been mitigated.Disclosure of relevant financial relationships are as follows:Dr. Nowak discloses the following relevant financial relationships with ineligible companies:Advisory Board/Consultant: Alexion (part of AstraZeneca), argenx, Amgen, Cour Pharmaceuticals, Immunovant, Janssen, UCBGrant/Research Support: Alexion (part of AstraZeneca), argenx, Amgen, Cour Pharmaceuticals, Immunovant, Janssen, UCBPlanners for this activity have no relevant financial relationships with any ineligible companies.This activity will review off-label or investigational information. The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.Method of ParticipationThere are no fees to participate in the activity.  Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the pre and post-program assessments. Your certificate will be emailed to you in within 30 days.Hardware/Software Requirements Windows Requirements: • Operating system: Windows XP Service Pack 2 or later • Browser: Internet Explorer 7 or later, Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connectionMacintosh Requirements: • Operating system: Mac OS X v10.3 or later • Browser: Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connectionPrivacyFor more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm  For more information about CheckRare's privacy policy, please access https://checkrare.com/privacy/ContactFor any questions, please contact: CEServices@academycme.orgCopyright© 2024. This CME-certified activity is held as copyrighted © by American Academy of CME and CheckRare CE. Through this notice, the Academy and CheckRare CE grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s). 

Quint and Allie talk through filing taxes jointly versus separately and why you would do either.